DAB2IP and breast carcinoma: Our results demonstrate the consequence of loss of DAB2IP in ER+ breast cancer, specifically focused on Luminal A breast cancer, and provide insight into underlying mechanisms that lead to the aggressiveness of this subset of tumors.